OSE Immunotherapeutics has made tangible progress across its clinical development pipeline, creating positive momentum, in our view. In immuno-inflammation, monoclonal antibody therapy lusvertikimab showed positive results in Phase II for ulcerative colitis (UC), and in immuno-oncology, cancer vacc
